Cannara Biotech Inc. has seen a modest uptick in its stock performance this week, driven by recent financial achievements.
Cannara Biotech Inc. (LOVE.TO) has experienced a positive week, with its stock price rising by 2.66% over the past week, closing at C$1.94 on the latest trading day. The company has garnered attention due to recent announcements regarding its financial performance and strategic initiatives.
Advertisement
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeMarket cap
$188.67M
P/E
17.4x
52W high
$2.05
52W low
$1.55
1W change
+2.66%
Beta
0.35
Analyst Price Targets
Based on analyst covering LOVE
Wall Street analysts forecast LOVE stock price to rise 74.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.38
+74.9% Upside
Current Price
C$1.93
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
40.0%
Annualized
90-Day Vol
36.2%
Annualized
Trend (90d)
+48.4%
Annualized drift
90d Mean
C$2.29
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.04 | C$1.78 – C$2.35 |
| 60 trading days | C$2.17 | C$1.78 – C$2.63 |
| 90 trading days | C$2.29 | C$1.81 – C$2.91 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors may view Cannara Biotech's recent growth in revenues and profitability as a positive indicator of its operational strength, alongside its ongoing efforts to expand its market presence.
Cannara's Q3 Revenue Hits C$31.8 Million
The company reported C$31.8 million in net revenues for Q3, indicating substantial growth and operational efficiency.
Bull case
Cannara's strong Q3 results, including record revenues and profitability, along with strategic acquisitions and partnerships, position the company for continued growth.
Bear case
Despite recent gains, the cannabis sector remains volatile. Cannara's performance could be affected by broader market trends and regulatory changes.
Recent Price Action
Cannara Biotech Inc. has shown a positive trend in its stock price this week, with a 1.05% increase on the latest trading day and a total gain of 2.66% over the week. Year-to-date, the stock has appreciated by 4.89%, reflecting gradual upward momentum.
Company News and Catalysts
Advertisement
This week, Cannara Biotech's stock movement can be attributed to its announcement of record Q3 revenues, totaling C$31.8 million, and an adjusted EBITDA of C$8.5 million. These results highlight the company's profitability and operational growth, helping to bolster investor confidence. Additionally, the company has been actively expanding its distribution network and enhancing its production capacity.
Technical Picture
From a technical perspective, Cannara Biotech's stock is currently trading above its 50-day moving average of C$1.75 and its 200-day moving average of C$1.77, indicating a bullish trend. The stock has a 52-week range of C$1.55 to C$2.05, with current pricing at 78% of that range. The stock's beta of 0.35 suggests lower volatility compared to the broader market, while the latest trading volume of 131,208 shares reflects a decrease compared to the 20-day average volume of 54,421 shares.
Insider Activity
No recent insider trading activity has been reported for Cannara Biotech, which may indicate stable management and confidence in the company's direction.
Price Action Summary
Cannara Biotech Inc. closed at C$1.94, reflecting a 1D increase of 1.05%. The stock continues to demonstrate positive momentum, supported by strong financial results and strategic initiatives.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
